Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings in Brief: Somnus Medical Technologies

This article was originally published in The Gray Sheet

Executive Summary

Somnus Medical Technologies: Plans for an initial public offering by Somnus are outlined in a preliminary prospectus filed with the Securities and Exchange Commission Sept. 11. The number of shares to be included in the offering and the price per share are yet to be determined but the filing values the IPO at up to $46 mil. A portion of the proceeds would be used to develop Somnus' domestic sales and marketing capabilities following the U.S. launch in July of the firm's first product, its Somnoplasty radiofrequency ablation system for treatment of snoring via reduction of soft tissue ("The Gray Sheet" Aug. 4, I&W-4).

Latest Headlines
See All
UsernamePublicRestriction

Register

MT008832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel